Changes in the Pathogenesis and Prevention of Chronic Lung Disease of Prematurity

 

 Buy Article Permissions and Reprints

ABSTRACT

With the increasing survival of extremely premature infants there is a large number of them who are developing chronic lung disease (CLD), but the severity of the lung damage is considerably less than that observed in the classic form of bronchopulmonary dysplasia (BPD). Because many of these infants have only a mild initial respiratory distress and therefore do not receive aggressive ventilation, it is clear that factors other than oxygen toxicity and barotrauma are involved in the pathogenesis of this new milder type of CLD. CLD results from the interaction of multiple factors that can injure the immature lung. For this reason the prevention must be based on the elimination of all the factors implicated in its pathogenesis. Clinical and epidemiological data strongly suggest that infections, either prenatal or nosocomial, and the presence of a patent ductus arteriosus (PDA) play a major role in the development of CLD in these infants. For this reason, efforts to prevent CLD in extremely low birth weight infants should include an aggressive approach to the prevention and treatment of prenatal and neonatal infections and an early closure of the PDA.

REFERENCES

• 1 Avery M E. Is chronic lung disease in low birth weight infants preventable?.  <~>A survey of eight centers. Pediatrics . 1987;  79 26
  PubMedGoogle Scholar
• 2 Northway Jr H W. Pulmonary disease following respirator therapy of hyaline membrane disease: bronchopulmonary dysplasia.  N Engl J Med . 1967;  276 357
  PubMedGoogle Scholar
• 3 Bancalari E. Bronchopulmonary dysplasia.  Pediatr Clin North Am . 1986;  33 1
  PubMedGoogle Scholar
• 4 Bancalari E. Bronchopulmonary dysplasia: clinical presentation.  J Pediatr . 1979;  95 819
  PubMedGoogle Scholar
• 5 Melnick G. Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia: an echocardiographic and pathologic study.  Pediatrics . 1980;  66 589
  PubMedGoogle Scholar
• 6 Groothius J R. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.  Pediatrics . 1988;  82 199
  PubMedGoogle Scholar
• 7 Blayney M. Bronchopulmonary dysplasia: improvement in lung function between 7 and 10 years of age.  J Pediatr . 1991;  118 201
  PubMedGoogle Scholar
• 8 Northway W H. Late pulmonary sequelae of bronchopulmonary dysplasia.  N Engl J Med . 1990;  323 1793
  Google Scholar
• 9 Bregman J, Farrell E E. Neurodevelopmental outcome in infants with bronchopulmonary dysplasia.  Clin Perinatol . 1992;  19 673-694
  PubMedGoogle Scholar
• 10 Markestad T. Growth and development in children recovering from bronchopulmonary dysplasia.  Pediatrics . 1986;  77 345
  PubMedGoogle Scholar
• 11 Abman S H. Late sudden unexpected deaths in hospitalized infants with bronchopulmonary dysplasia.  Am J Dis Child . 1989;  143 815
  PubMedGoogle Scholar
• 12 Gray P H. Are infants with bronchopulmonary dysplasia at risk for sudden infant death syndrome?.  Pediatrics . 1994;  93 774
  PubMedGoogle Scholar
• 13 Werthammer J. Sudden infant death syndrome in infants with bronchopulmonary dysplasia.  Pediatric . 1982;  69 301
  PubMedGoogle Scholar
• 14 Rojas M A, Gonzalez A, Bancalari E. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.  J Pediatr . 1995;  126 605-601
  CrossrefPubMedGoogle Scholar
• 15 Marshall D D, Kotelchuck M, Young T E, Bose C L, Kruyer L, O'Shea M, and the North Carolina Neonatologist Association. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants.  Pediatrics . 1999;  104 1345-1350
  CrossrefPubMedGoogle Scholar
• 16 Pierce M R, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia.  Pediatr Pulmonol . 1995;  19 371-378
  PubMedGoogle Scholar
• 17 Couroucli X I, Welty S E, Ramsay P L. Detection of microorganisms in tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia.  Pediatr Res . 2000;  47 225-232
  CrossrefPubMedGoogle Scholar
• 18 Matsuda T, Nakajima T, Hattori S. Necrotizing funisitis: clinical significance and association with chronic lung disease in premature infants.  Am J Obstet Gynecol . 1997;  177 1402-1407
  PubMedGoogle Scholar
• 19 Watterberg K L, Demers L M, Scott S M, Murphy S. Chorioamniotis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.  Pediatrics . 1996;  97 210-215
  CrossrefPubMedGoogle Scholar
• 20 Yoon B H, Romero R, Jun J K. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-á, interleukin-1â, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia.  Am J Obstet Gynecol . 1997;  177 825-830
  CrossrefPubMedGoogle Scholar
• 21 Yoon B H, Romero R, Kim K S. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia.  Am J Obstet Gynecol . 1999;  181 773-779
  CrossrefPubMedGoogle Scholar
• 22 Cassell G H, Crouse D T, Cannup K C, Waites K B, Rudd P T, Stagno S. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very low birth weight infants.  Lancet . 1988;  2 240-244
  PubMedGoogle Scholar
• 23 Sanchez P J, Regan J A. Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants.  Pediatr Infect Dis J . 1988;  7 542-546
  PubMedGoogle Scholar
• 24 Wang E L, Ohlsson A, Kellner J D. Association of ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of meta-analysis.  J Pediatr . 1995;  127 640-644
  PubMedGoogle Scholar
• 25 Groneck P, Gotze-Speer B, Oppermann M. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates.  Pediatrics . 1994;  93 712-781
  PubMedGoogle Scholar
• 26 Mirro R, Armstead W, Leffler C. Increased airway leukotriene levels in infants with severe bronchopulmonary dysplasia.  Am J Dis Child . 1990;  144 160-161
  PubMedGoogle Scholar
• 27 Brus F, Oeveren W, Okken A. Activation of circulating polymorphonuclear leukocytes in preterm infants with severe idiopathic respiratory distress syndrome.  Pediatr Res . 1996;  456-463
  PubMedGoogle Scholar
• 28 Carlton D P, Albertine K H, Cho S C. Role of neutrophils in lung vascular injury and edema after premature birth in lambs.  J Appl Physiol . 1997;  83 1307-1317
  Google Scholar
• 29 Gerdes J S, Yoder M C, Douglas S D, Paul M, Harris M C, Polin R A. Tracheal lavage and plasma fibronectin: relationship to respiratory distress syndrome and development of bronchopulmonary dysplasia.  J Pediatr . 1986;  108 601-606
  PubMedGoogle Scholar
• 30 Ogden B E, Murphy S A, Saunders G C, Pathak D, Johnson J D. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance.  Am Rev Respir Dis . 1984;  130 817-821
  PubMedGoogle Scholar
• 31 Walti H, Tordet C, Gerbaut L. Persistent elastase/ proteinase inhibitor imbalance during prolonged ventilation of infants with BPD: evidence for the role of nosocomial infections.  Pediatr Res . 1989;  26 351-355
  PubMedGoogle Scholar
• 32 Watterberg K L, Carmichael D F, Gerdes J S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia.  J Pediatr . 1994;  125 264-269
  PubMedGoogle Scholar
• 33 Bruce M C, Wedig K E, Jentoft N. Altered urinary excretion of elastin cross-links in premature infants who develop bronchopulmonary dysplasia.  Am Rev Resp Dis . 1985;  131 568-572
  PubMedGoogle Scholar
• 34 Gonzalez A, Sosenko I RS, Chandar J. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighting 1000 grams or less.  J Pediatr . 1996;  128 470-478
  CrossrefPubMedGoogle Scholar
• 35 Varsila E, Hallman M, Venge P. Closure of patent ductus arteriosus decreases pulmonary Myeloperoxidase in premature infants with respiratory distress syndrome.  Biol Neonate . 1995;  67 167-171
  PubMedGoogle Scholar
• 36 Van Marter J L. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia.  Pediatrics . 1990;  86 331
  PubMedGoogle Scholar
• 37 Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial.  Pediatrics . 1990;  82 683-690
  PubMedGoogle Scholar
• 38 Albertine K H, Jones G P, Starcher B C. Chronic lung injury in preterm lambs. Disordered respiratory tract development.  Am J Respir Crit Care Med . 1999;  159 945-958
  PubMedGoogle Scholar
• 39 Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies.  Am J Respir Crit Care Med . 1998;  157 294-323
  CrossrefPubMedGoogle Scholar
• 40 Gerstmann D R, deLemos R A, Coalson J J, Clark R H, Wiswell T E, Winter D C, Kuehl T J, Meredith K S, Null Jr M D. Influence of ventilatory technique on pulmonary baro injury in baboons with hyaline membrane disease.  Pediatr Pulmonol . 1988;  5 82-91
  PubMedGoogle Scholar
• 41 Bjorklund L J, Ingimarsson J, Curstedt T. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs.  Pediatr Res . 1997;  42 348-355
  CrossrefPubMedGoogle Scholar
• 42 Wada K, Jobe A H, Ikegami M. Tidal volume effects on surfactant treatment responses with the initiation of ventilation in preterm lambs.  J Appl Physiol . 1997;  83 1054-1061
  PubMedGoogle Scholar
• 43 Jackson J C. Reduction in lung injury after combined surfactant and high-frequency ventilation.  Am J Resp Crit Care Med . 1994;  150 534
  PubMedGoogle Scholar
• 44 HIFI Study Group. High frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants.  N Engl J Med . 1989;  320 88
  PubMedGoogle Scholar
• 45 Thome U, Kossel H, Lopowsky G. Randomized comparison of high-frequency ventilation with high-rate intermittent positive pressure ventilation in preterm infants with respiratory failure.  J Pediatr . 1999;  135 39-46
  PubMedGoogle Scholar
• 46 Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation.  Biol Neonate . 1980;  38 96-105
  CrossrefPubMedGoogle Scholar
• 47 Cotton R B, Stahlman M T, Bender H W, Graham T P, Catterton W Z, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants.  J Pediatr . 1978;  93 647-651
  CrossrefPubMedGoogle Scholar
• 48 Brown E R. Bronchopulmonary dysplasia possible relationship to pulmonary edema.  J Pediatr . 1978;  92 982
  CrossrefPubMedGoogle Scholar
• 49 Bell E F. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants.  N Engl J Med . 1980;  392 598
  PubMedGoogle Scholar
• 50 Tammela O KT. Fluid restriction for preventing bronchopulmonary dysplasia?.  <~>Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr . 1992;  81 201
  PubMedGoogle Scholar
• 51 Van Marter J L. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants.  J Pediatr . 1990;  116 942
  Google Scholar
• 52 Albersheim S G. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia.  J Pediatr . 1989;  115 615
  PubMedGoogle Scholar
• 53 Engelhardt B. Short- and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia.  J Pediatr . 1986;  109 1034
  PubMedGoogle Scholar
• 54 Kao L C. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia, J Pediatr .  1983;  103 624
  PubMedGoogle Scholar
• 55 Kao L C. Randomized trial of long-term diuretic therapy for infants with oxygen- dependent bronchopulmonary dysplasia.  J Pediatr . 1994;  124 772
  Google Scholar
• 56 Berner M E. Furosemide reduces lung fluid filtration in lambs with lung microvascular injury from air embolic.  J Appl Physiol . 1989;  67 1990
  PubMedGoogle Scholar
• 57 Frank L, Groseclose E E. Oxygen toxicity in newborns: the adverse effects of under nutrition.  J Appl Physiol . 1982;  53 1248-1255
  PubMedGoogle Scholar
• 58 Hustead V A, Gutcher G R, Anderson S A, Zachman R D. Relationship of vitamin A (retinol) status to lung disease in the preterm infant.  J Pediatr . 1984;  105 610-615
  PubMedGoogle Scholar
• 59 Shenai J P, Chytil F, Stahlman M T. Vitamin A status of neonates with bronchopulmonary dysplasia.  Pediatr Res . 1985;  19 185-189
  CrossrefPubMedGoogle Scholar
• 60 Shenai J P, Kennedy K A, Chytil F, Stahlman M T. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia.  J Pediatr . 1987;  111 269-277
  PubMedGoogle Scholar
• 61 Shenai J P. Vitamin A supplementation in very low birth weight neonates: rational and evidence.  Pediatrics . 1999;  104 1369-1374
  CrossrefPubMedGoogle Scholar
• 62 Tyson J E, Wright L L, Oh W, Kennedy K A, Mele L, Ehrenkranz R A, Stoll B J, Lemons J A, Stevenson D K, Bauer C R, Korones S B, Fanaroff A A, and the National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely-low-birth-weight infants.  N Engl J Med . 1999;  340 1962-1968
  CrossrefPubMedGoogle Scholar
• 63 Bancalari E. Corticosteroids and neonatal chronic lung disease.  Eur J Pediatr . 1998;  157 S31-S37
  PubMedGoogle Scholar
• 64 Co E, Chari G, McCulloch K, Vidyasagar D. Dexamethasone treatment suppresses collagen synthesis in infants with bronchopulmonary dysplasia.  Pediatr Pulmonol . 1993;  16 36-40
  PubMedGoogle Scholar
• 65 Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial.  Pediatrics . 1991;  88 421-427
  PubMedGoogle Scholar
• 66 Avery G B, Fletcher A B, Kaplan M, Brudno D S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.  Pediatrics . 1985;  75 106-111
  CrossrefPubMedGoogle Scholar
• 67 Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease.  Arch Dis Child Fetal Neonatal . 1998;  79 F26-33
  PubMedGoogle Scholar
• 68 Georgieff M K, Mammel M C, Mills M M, Gunter E W, Johnson D E, Thompson T R. Effect of postnatal steroid administration on serum vitamin A concentrations in newborn infants with respiratory compromise.  J Pediatr . 1989;  114 301-304
  PubMedGoogle Scholar
• 69 Groneck P, Reuss D, Götze-Speer B, Speer C P. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.  J Pediatr . 1993;  122 938-944
  PubMedGoogle Scholar
• 70 Ellington B, McBride J T, Stokes D C. Effects of corticosteroids on postnatal lung and airway growth in the ferret.  J Appl Physiol . 1990;  68 2029-2033
  PubMedGoogle Scholar
• 71 Papile L A, Tyson J E, Stoll B J. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants.  N Engl J Med . 1998;  338 1112
  CrossrefPubMedGoogle Scholar
• 72 Tsai F-J, Tsai C-H, Wu S-F, Liu Y-H, Yeh T-F. Catabolic effect in premature infants with early dexamethasone treatment.  Acta Paediatr . 1996;  85 1487-1490
  PubMedGoogle Scholar
• 73 Tschanz S A, Damke B M, Burri P H. Influence of postnatally administered glucocorticoids on rat lung growth.  Biol Neonate . 1995;  68 229-245
  PubMedGoogle Scholar
• 74 Werner J C. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia.  J Pediatr . 1992;  120 286
  PubMedGoogle Scholar
• 75 O'Shea T M, Kothadia J M, Klinepeter K L, Goldstein D J, Jackson B, Dillard R G. Follow-up of preterm infants treated with dexamethasone for chronic lung disease.  Am J Dis Child . 1993;  147 658-661
  PubMedGoogle Scholar
• 76 O'Shea T M, Kothadia J M, Klinepeter K L. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.  Pediatrics . 1999;  104 15-21
  CrossrefPubMedGoogle Scholar
• 77 Yeh T F, Lin Y J, Huang C C, Chen Y J, Lin C H, Lin H C. Early dexamethasone therapy in preterm infants: a follow-up study.  Pediatrics . 1998;  101 E7
  PubMedGoogle Scholar
• 78 Brozanski B S, Jones J G, Gilmour C H. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant.  J Pediatr . 1995;  126 769-776
  PubMedGoogle Scholar
• 79 Cloutier M M, McLellan N. Nebulized steroid therapy in bronchopulmonary dysplasia.  Pediatr Pulmonol . 1993;  15 111-116
  PubMedGoogle Scholar
• 80 LaForce W R, Brudno D S. Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependent infants.  J Pediatr . 1993;  122 285-288
  PubMedGoogle Scholar
• 81 Cole C H, Colton T, Shah B L. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.  N Engl J Med . 1999;  340 1005-1010
  CrossrefPubMedGoogle Scholar